ACY-775
CAS No. 1375466-18-4
ACY-775 ( ACY 775 | ACY775 )
产品货号. M11553 CAS No. 1375466-18-4
ACY-775 (ACY775) 是一种有效且特异性的 HDAC6 抑制剂 (IC50=7.5 nM),具有改善的大脑生物利用度。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥348 | 有现货 |
|
| 5MG | ¥583 | 有现货 |
|
| 10MG | ¥988 | 有现货 |
|
| 25MG | ¥2066 | 有现货 |
|
| 50MG | ¥3345 | 有现货 |
|
| 100MG | ¥5006 | 有现货 |
|
| 500MG | ¥10773 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ACY-775
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述ACY-775 (ACY775) 是一种有效且特异性的 HDAC6 抑制剂 (IC50=7.5 nM),具有改善的大脑生物利用度。
-
产品描述ACY-775 (ACY775) is a potent and specific HDAC6 inhibitor (IC50=7.5 nM) with improved brain bioavailability; 60-1500 fold selectivity over class I HDACs; no activity against all other class II HDAC isoforms (IC50>1?uM); induce dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors; increases the innervation of the neuromuscular junctions in the gastrocnemius muscle and improves the motor and sensory nerve conduction in the mutant HSPB1-induced CMT2 mouse model.
-
体外实验In vehicle-treated cells, α-tubulin is mainly presented in the deacetylated form, while histone 3 is clearly acetylated. Upon treatment with ACY-775, a clear enhancement of the acetylation of α-tubulin is visible, while histone acetylation remains unaltered. Acetylation of α-tubulin is visualized by immunofluorescence and the intensity in the neurites of the neurons is quantified and normalized to the length of the fluorescent signal. In vehicle-treated DRG neurons, acetylated α-tubulin is already present. Upon treatment with ACY-775 the signal intensity of acetylated α-tubulin increases significantly. Significant increase in motility of mitochondria and also the total number of mitochondria within the neurites are observed compare with vehicle-treated DRG neurons. A significantly higher number of retrogradely transport mitochondria is observed in DRG neurons treated with ACY-775 compare with vehicle-treated cells.
-
体内实验Biodistribution profiles of ACY-738, ACY-775, and tubastatin A are examined after acute dosing at 5 or 50?mg/kg over 2?h. At t=30?min after acute 50?mg/kg injection, respective plasma levels of ACY-738 and ACY-775 are 515?ng/mL (1.9?μM) and 1359?ng/mL (4.1?μM). Elimination from plasma is rapid, with plasmatic half-life of 12?min and concentration below 10?ng/mL after 2?h. Nevertheless, areas under concentration time curves for brain and plasm calculated over 2?h for both ACY-738 and ACY-775 lead to ratios >1. When ACY-738 (5?mg/kg) or ACY-775 (50?mg/kg) are administered repeatedly in wild-type mice at 24?h, 4?h, and 30?min before killing, significant increases in α-tubulin acetylation are observed in all tested brain regions.
-
同义词ACY 775 | ACY775
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC
-
研究领域——
-
适应症——
化学信息
-
CAS Number1375466-18-4
-
分子量330.36
-
分子式C17H19FN4O2
-
纯度>98% (HPLC)
-
溶解度DMSO : 100 mg/mL 302.70 mM
-
SMILESO=C(C1=CN=C(NC2(C3=CC=CC(F)=C3)CCCCC2)N=C1)NO
-
化学全称2-((1-(3-fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Jochems J, et al. Neuropsychopharmacology. 2014 Jan;39(2):389-400.
2. Benoy V, et al. Neurotherapeutics. 2017 Apr;14(2):417-428.
产品手册
关联产品
-
GSK-3117391
GSK-3117391 (CHR-5154) 是一种新型巨噬细胞靶向 HDAC 抑制剂。
-
NVP-BSK805 2HCl
NVP-BSK805 2HCl(IC50=0.5 nM)是一种特异性有效的ATP竞争性JAK2抑制剂,其特异性是JAK1、JAK3和TYK2的20倍以上。
-
TH34
TH34 是一种 HDAC6/8/10 抑制剂 (IC50: 4.6/1.9/7.7 μM)。它比 HDAC1/2/3 显示出更高的选择性。
021-51111890
购物车()
sales@molnova.cn

